Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.
Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Noortje
N
van Herwaarden
Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Chantal A M
CA
Bouman
Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Aatke
A
van der Maas
ClinTRID, Karolinska Institute, Stockholm, Sweden.
Ronald F
RF
van Vollenhoven
Department of Rheumatology & Clinical Immunology, Utrecht University Medical Centre, Utrecht, The Netherlands.
Johannes W
JW
Bijlsma
Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Frank H J
FH
van den Hoogen
Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Alfons A
AA
den Broeder
Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
Bart J F
BJ
van den Bemt
D000068879:Adalimumab / Q000097:blood / Q000494:pharmacology*; D018501:Antirheumatic Agents / Q000493:pharmacokinetics; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D000068800:Etanercept / Q000493:pharmacokinetics*; D006801:Humans
D018501:Antirheumatic Agents; D000068879:Adalimumab; D000068800:Etanercept
Anti-TNF; Epidemiology; Rheumatoid Arthritis